View in EDS

321P Results of an open-label, single-arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC).

Saved in:
Bibliographic Details
Title: 321P Results of an open-label, single-arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC).
Authors: Roderburg, C.1 (AUTHOR), Gonzalez Carmona, M.A.2 (AUTHOR), Berres, M-L.3 (AUTHOR), Modest, D.P.4 (AUTHOR), Mohr, R.5 (AUTHOR), Wree, A.6 (AUTHOR), Venerito, M.7 (AUTHOR), Keitel, V.8 (AUTHOR), Waldschmidt, D.T.9 (AUTHOR), Lüdde, T.10 (AUTHOR), Kehmann, L.11 (AUTHOR)
Source: Annals of Oncology. 2025 Supplement 1, Vol. 36, pS125-S125. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2025.05.336